Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

Published Date: 29 May 2026

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Read Full News

Latest News

Transperineal Biopsy IDs Active Surveillance Candidates

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

The Clues Hidden in Failed Prostate Cancer Trials

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Palliative Care Remains Uncommon in Young Adults With Cancer

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Latest News

Transperineal 3D mapping biopsy may help select patients with low-risk prostate cancer who are most likely to fare well with active surveillance.

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

Concurrent palliative care use among young adults with advanced cancer is less than 20%, with substantial variation across cancer types.

In high-risk low-grade glioma, starting with temozolomide or radiotherapy yields similar survival.

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

News All Time

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

AI-Driven Biomarker Predicts Prostate Cancer Outcomes

The tool, based on histology only, may help identify patients most likely to benefit from triplet therapy.

Community Oncology Well Suited for Advanced Cancer Patients

Experts tout common characteristics of local physician practices that are beneficial to those with advanced disease.

Real-World EV Plus Pembro Success Seen in Urothelial Cancer

A retrospective study evaluates outcomes associated with first-line enfortumab vedotin plus pembrolizumab vs gemcitabine plus cisplatin in patients with metastatic urothelial carcinoma.

Germline Variants Predict Lobular Breast Cancer Recurrence

For women with invasive lobular carcinoma, pathogenic variants in breast cancer risk genes predict high odds of early recurrence.

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma, who were ineligible for autologous stem cell transplant, were randomly assigned to receive Pola-R-GemOx or R-GemOx.

MRI Enhancement Predicts Breast Cancer in BRCA Carriers

Higher background parenchymal enhancement on breast MRI may signal greater risk among women who carry BRCA mutations.

Breast Cancer Incidence Rises in Asian American Women

A cross-sectional population-based study examines trends in invasive breast cancer incidence rates in Asian American, Native Hawaiian, and Pacific Islander ethnic groups.

Asian Women With Breast Cancer Outlive White Peers

Researchers seek to understand why Asian women fare better with the disease.

FDA Approves Orca‑T, a Next‑Gen HSCT to Reduce GVHD

By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.

Combined Models With AI Improve Breast Cancer Prediction

Combining mammography AI, polygenic, and clinical risk models improves 10-year breast cancer risk prediction compared with any single model.

Induction Immunotherapy Has Durable Survival Benefit in LACC

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Time to Rethink Maintenance Pemetrexed in NSCLC?

For patients with advanced non-small cell lung cancer (NSCLC), adding pemetrexed to maintenance pembrolizumab may only increase toxicity, not survival.

Recommended News For You

PSMA PET: Prostate Cancer Staging Revolution Awaits RCT Data

Researchers identify potential new therapeutic targets for treating T-cell lymphoma and natural killer cell tumors.

Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

Using MRD Status to Deescalate Multiple Myeloma Therapy

The Early Progression of Prostate Cancer Is Not Stopped by Metformin.

Checking PSA levels too soon after prostate cancer surgery can lead to overtreatment, study suggests

Recommended Articles For You

Anemia in Older Adults: Causes, Clinical Impact, and Evidence-Based Management 

What You Need To Know About Secondary Polycythemia: Treatment & Symptoms 

The Digital Revolution in Oncology - How Software, AI, and Data are Reshaping Cancer Care by 2025 

Understanding Neutropenic Fever: What It Is and Why it's a Serious Concern  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Bayer is transforming pharmaceutical research into women's health

2.

Palliative Care Remains Uncommon in Young Adults With Cancer

3.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

4.

Trial Supports Ivonescimab and Chemo for NSCLC Survival

5.

healthy despite having advanced cancer.

1.

Modern Strategies in Hematology for Specialists

2.

Clinical Insights in Hematology in Daily Practice

3.

Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options 

4.

Tumor Evolution Dynamics and Clinical Prognosis

5.

Reconstructive Tissue Engineering After Tumor Resection

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

2.

Thromboprophylaxis In Medical Settings- An Update

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

4.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV

5.

Efficient Management of First line ALK-rearranged NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot